Status:

RECRUITING

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

Lead Sponsor:

iHealthScreen Inc

Collaborating Sponsors:

National Institutes of Health (NIH)

Conditions:

Diabetes

Diabetic Retinopathy

Eligibility:

All Genders

22+ years

Brief Summary

In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in...

Detailed Description

In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in...

Eligibility Criteria

Inclusion

  • Age of Subjects: Patients ≥ 22 years of age.
  • Gender of Subjects: Both males and females will be invited to participate.
  • Subjects with diabetes (A1C level ≥ 6.5).
  • Subjects must be willing and are able to comply with clinic visit, understand the study-related procedures/provisions, and provide signed informed consent.

Exclusion

  • Unable to understand the study, Our unable to or unwilling to sign the informed consent
  • Previously diagnosed with macular edema, any form of diabetic retinopathy, radiation retinopathy, or retinal vein occlusion
  • participants who are experiencing persistent vision loss, blurred vision, or other vision problems that should be evaluated by an eye care provider
  • subjects whose retinal images were used in training, validating, or developing the device
  • Currently participating in another investigational eye study or actively receiving investigational product for DR or DME.
  • A condition that, in the opinion of the investigator, would preclude participation in the study;
  • Contraindicated for imaging by fundus imaging systems used in the study because of hypersensitivity to light, recently underwent photodynamic therapy, or was taking medication that causes photosensitivity.

Key Trial Info

Start Date :

January 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 31 2027

Estimated Enrollment :

922 Patients enrolled

Trial Details

Trial ID

NCT07151001

Start Date

January 1 2025

End Date

July 31 2027

Last Update

September 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

iHealthScreen Inc.

Richmond Hill, New York, United States, 11418

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy | DecenTrialz